MiNK Therapeutics (INKT) grants 5,395 options to director Brian Corvese

Rhea-AI Filing Summary

MiNK Therapeutics director Brian Corvese received a new stock option grant. On January 2, 2026, he was awarded options to buy 5,395 shares of MiNK Therapeutics common stock at an exercise price of $11.12 per share. These options vest on February 2, 2026, as long as he continues to serve on the company’s board through that date. The options expire on January 2, 2036, and were acquired at a price of $0.00, reflecting a compensatory equity award rather than a market purchase.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Corvese Brian

(Last) (First) (Middle)

149 FIFTH AVENUE, SUITE 500

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MiNK Therapeutics, Inc. [ INKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$11.12	01/02/2026		A		5,395		(1)	01/02/2036	Common Stock	5,395	$0.00	5,395	D

Explanation of Responses:

1. Option vests on February 2, 2026, provided that the Reporting Person continues to serve on the Issuer's Board of Directors through such date.

	By: /s/ Austin Charette, Attorney-in-Fact	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did MiNK Therapeutics (INKT) report for Brian Corvese?

MiNK Therapeutics reported that director Brian Corvese received a grant of stock options for 5,395 shares of common stock on January 2, 2026.

What are the key terms of Brian Corvese’s MiNK Therapeutics stock options?

The stock options cover 5,395 shares of common stock at an exercise price of $11.12 per share, with an expiration date of January 2, 2036.

When do Brian Corvese’s MiNK Therapeutics options vest?

The options vest on February 2, 2026, provided that Brian Corvese continues to serve on MiNK Therapeutics’ board of directors through that date.

Did Brian Corvese pay anything to receive these MiNK Therapeutics options?

The filing shows the options were acquired at a price of $0.00 per derivative security, indicating they were granted as compensation rather than purchased in the market.

How many MiNK Therapeutics derivative securities does Brian Corvese hold after this grant?

After the reported transaction, Brian Corvese beneficially owned 5,395 stock options, all held with direct ownership.

What role does Brian Corvese have at MiNK Therapeutics (INKT)?

The filing identifies Brian Corvese as a director of MiNK Therapeutics. He is not reported as an officer or a 10% owner in this form.